Fig 1.
VTE: venous thromboembolism.
Table 1.
Descriptive baseline characteristics among VTE patients at and not at a high risk of bleeding.
Table 2.
Descriptive pre- and post-IPTW baseline characteristics among VTE patients at a high risk of bleeding that initiated apixaban vs warfarin.
Fig 2.
Risk of recurrent VTE, major bleeding, and CRNM bleeding for apixaban vs. warfarin among VTE patients at a high risk of bleeding.
Fig 3.
Risk of recurrent VTE, major bleeding, and CRNM bleeding for apixaban vs. warfarin among VTE patients at a high risk of bleeding stratified by number of risk factors and type of risk factors.